logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Marinus van Hulst

Martini Hospital
H指数:17
被引数:976

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Retraction Notice to “Effect of subcutaneous lidocaine–hydroxypropyl-β-cyclodextrin (HP-β-CD) on quality of life in patients with post-COVID condition: a 36-week observational interrupted time series study” [eClinicalMedicine 90(2025) 103681]

撤稿声明：“皮下利多卡因–羟丙基-β-环糊精（HP-β-CD）对后COVID状态患者生活质量的影响：一项36周的观察性中断时间序列研究” [eClinicalMedicine 90(2025) 103681]

eClinicalMedicine
IF10
2026-03-120
OAAI
Cees-Jan Oostwouder; Karin Vos; Ivo J. Lutke Schipholt; Mathijs R. Merkus; Thomas Telders; David F.A. van Deursen; Max B. de Smit; Marina D. van Eijk; Hetty J. Bontkes; Femke H. Bouwman; Rob C.I. Wüst; Lara de Jong; Marinus van Hulst; Jos W.R. Twisk; Coenraad K. van Kalken; Gwendolyne G.M. Scholten-Peeters
Effect of subcutaneous lidocaine–hydroxypropyl-β-cyclodextrin (HP-β-CD) on quality of life in patients with post-COVID condition: a 36-week observational interrupted time series study

皮下利多卡因–羟丙基-β-环糊精（HP-β-CD）对后COVID状态患者生活质量的影响：一项为期36周的观察性中断时间序列研究

eClinicalMedicine
IF10
2025-12-030
OAAI
Cees-Jan Oostwouder; Karin Vos; Ivo J. Lutke Schipholt; Mathijs R. Merkus; Thomas Telders; David F.A. van Deursen; Max B. de Smit; Marina D. van Eijk; Hetty J. Bontkes; Femke H. Bouwman; Rob C.I. Wüst; Lara de Jong; Marinus van Hulst; Jos W.R. Twisk; Coenraad K. van Kalken; Gwendolyne G.M. Scholten-Peeters
Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy

曲妥珠单抗Deruxtecan在接受过化疗的不可切除或转移性HER2-Low乳腺癌患者中的成本效益

ADVANCES IN THERAPY
IF4
2024-11-120
OAAI
Paulissen, Jeroen Hendrikus Jacobus; van Schoonhoven, Alexander Victor; Olin, Emma; Postma, Arjan Jacobus; Mbanya, Zacharie; Dunton, Kyle John; Postma, Maarten Jacobus; van Hulst, Marinus; Freriks, Roel Donald
Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland

曲妥珠单抗deruxtecan作为芬兰HER2-positive不可切除和/或转移性乳腺癌二线治疗的成本效益模型

EUROPEAN JOURNAL OF HEALTH ECONOMICS
IF3
2023-07-244
OAAI
Paulissen, Jeroen H. J.; Seddik, Ahmed H. H.; Dunton, Kyle J. J.; Livings, Christopher J. J.; van Hulst, Marinus; Postma, Maarten J. J.; de Jong, Lisa A. A.; Freriks, Roel D. D.

研究方向

暂未获取到该数据
M
Maarten J. Postma
H 指数:91论文数:1,513被引数:14.5万
R
Robert G Tieleman
H 指数:35论文数:118被引数:5,187
M
Maartje S. Jacobs
H 指数:8论文数:26被引数:287
F
Femke H. Bouwman
H 指数:60论文数:314被引数:1.1万
M
Mayowa Owolabi
H 指数:103论文数:572被引数:20.6万
J
Jeroen Paulissen
H 指数:4论文数:13被引数:78
K
Kwasi Torpey
H 指数:32论文数:203被引数:4,038
L
Lisa A. de Jong
H 指数:11论文数:40被引数:273
R
Roel Freriks
H 指数:6论文数:28被引数:130
C
Cees-Jan Oostwouder
H 指数:1论文数:3被引数:2